SCHEMBL7708149

SCHEMBL7708149

CC1Oc2ccc(CN(Cc3ccc(F)cc3)C(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 8/20 0.45
HSD17B10 Q99714 2/20 0.38
ALOX15 P16050 1/20 0.38
SMYD3 Q9H7B4 2/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36
TP53 P04637 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
KCNQ4 P56696 1/20 0.36
KCNQ5 Q9NR82 1/20 0.36
GRM2 Q14416 1/20 0.35
DAO P14920 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7713256 0.92 PARP1 (0.48) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL7713376 0.91 PARP1 (0.56) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL7713299 0.91 PARP1 (0.46) PARP1HSD17B10ALOX15USP2GAA
SCHEMBL7713340 0.90 PARP1 (0.47) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL6305893 0.89 PARP1 (0.54) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL7704932 0.89 HDAC3 (0.35) PARP1HSD17B10ALOX15TP53HDAC3
SCHEMBL7711373 0.89 PARP1 (0.44) PARP1HSD17B10ALOX15SMYD3USP2
SCHEMBL7708033 0.89 PARP1 (0.45) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL7708088 0.89 PARP1 (0.47) PARP1HSD17B10ALOX15SMYD3PDE3B
SCHEMBL7708225 0.88 PARP1 (0.43) PARP1HSD17B10ALOX15SMYD3PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed